Discussion of Real-World Myeloma Care Emphasizes Value of Personalized Medicine
Samer A. Al’Hadidi, MD, discusses the importance of personalized medicine in patients with multiple myeloma.
Samer A. Al’Hadidi, MD, assistant professor in the Department of Internal Medicine — Division of Hematology and Oncology at UAMS Winthrop P. Rockefeller Cancer Institute in Little Rock, Arkansas, discusses the importance of personalized medicine in patients with multiple myeloma.
At a Case-Based Roundtable event, Al’Hadidi moderated a discussion on newly diagnosed and relapsed multiple myeloma cases. One of his takeaways was that participants discussed their patients in clinical practice which differ from those who benefited from regimens proven efficacious in clinical trials such as frontline quadruplet combinations and chimeric antigen receptor T-cell therapies.
Participants brought up patients who may have issues with caregiver availability, distance from care centers, and social events that prevent them from receiving intensive treatments. Al’Hadidi said this is an important reminder that each patient’s characteristics are different and may lead the treating physician to seek therapies that have less logistical obstacles or fewer toxicities. The discussion helped explore what factors outside trial data affect patients in clinic and how physicians can select the optimal therapy.
TRANSCRIPTION:
0:10 | I think these case-based events are very important because they actually provide data on patients that you can see in the clinical practice where they differ from patients who are enrolled in clinical trials and may not be really the patients you read about. They may be different. And we always think about what we call personalized medicine, and that is really true, because there are patients, for example, who may have issues with caregiver. They may have distance from the treating location where they get their treatments. They may also have some social events in their life that prevent them from doing, for example, an intensive treatment at a given time.
0:50 | So I think those discussions are very important, because each patient is a scenario that we need to take it by its characteristics, and decide on what will be best. So such opportunities to discuss such patients are important.
So you can see many of the attendees discussing some of their own cases they see and the challenges they find. And that brings up actually, more brainstorming on what will be best for this given patient. That may not be necessarily the thing that is done on a clinical trial basis, but rather on how you treat patients in clinic.
Supportive Care Helps Manage AEs With Teclistamab in R/R Multiple Myeloma
December 13th 2024During a Case-Based Roundtable® event, Hana Safah, MD, discussed updated data and adverse event management related to teclistamab in patients with multiple myeloma in the second article of a 2-part series.
Read More
